参考文献/References:
[1] Hielscher A,Gerecht S.Hypoxia and free radicals:Role in tumor progression and the use of engineering-based platforms to address these relationships[J].Free Radic Biol Med,2015,79:281-291.DOI:10.1016/j.freeradbiomed.2014.09.015.
[2] Halmos GB,Bruine de Bruin L,Langendijk JA,et al.Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside(18F-FAZA)-PET:a review[J].Clin Nucl Med,2014,39(1):44-48.DOI:10.1097/RLU.0000000000000286.
[3] Padhani AR.Where are we with imaging oxygenation in human tumours?[J].Cancer Imaging,2005,5:128-130.DOI:10.1102/1470-7330.2005.0103.
[4] Vaupel P,Mayer A.The clinical importance of assessing tumor hypoxia:Relationship of tumor hypoxia to prognosis and therapeutic opportunities[J].Antioxid Redox Signal,2015,22(10):878-880.DOI:10.1089/ars.2014.6155.
[5] Carreau A,El Hafny-Rahbi B,Matejuk A,et al.Why is the partial oxygen pressure of human tissues a crucial parameter?Small molecules and hypoxia[J].J Cell Mol Med,2011,15(6):1239-1253.DOI:10.1111/j.1582-4934.2011.01258.x.
[6] Bourgeois M,Rajerison H,Guerard F,et al.Contribution of[64cu]-atsm pet in molecular imaging of tumour hypoxia compared to classical[18f]-miso-a selected review[J].Nucl Med Rev Cent East Eur,2011,14(2):90-95.DOI:10.5603/NMR.2011.00022.
[7] Marcu LG,Harriss-Phillips WM,Filip SM.Hypoxia in head and neck cancer in theory and practice:A pet-based imaging approach[J/OL].Comput Math Methods Med,2014,2014:624642[2015-09-09].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158154.DOI:10.1155/2014/624642.
[8] Garcia C,Flamen P.Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era[J].Curr Opin Oncol,2008,20(3):275-279.DOI:10.1097/CCO.0b013e3282faa0cb.
[9] Kumar P,Ohkura K,Beiki D,et al.Synthesis of 1-beta-D-(5-deoxy-5-iodoarabinofuranosyl)-2-nitroimidazole(beta-IAZA):A novel marker of tissue hypoxia[J].Chem Pharm Bull(Tokyo),2003,51(4):399-403.DOI:10.1248/cpb.51.399.
[10] Souvatzoglou M,Grosu AL,R?per B,et al.Tumour hypoxia imaging with[18F]FAZA PET in head and neck cancer patients:a pilot study[J].Eur J Nucl Med Mol Imaging,2007,34(10):1566-1575.DOI:10.1007/s00259-007-0424-3.
[11] Thomlinson RH,Gray LH.The histological structure of some human lung cancers and the possible implications for radiotherapy[J].Br J Cancer,1955,9(4):539-549.
[12] Overgaard J,Hansen HS,Overgaard M,et al.A randomized double-blind phase Ⅲ study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma.Results of the Danish Head and Neck Cancer Study(DAHANCA)Protocol 5-85[J].Radiother Oncol,1998,46(2):135-146.DOI:10.1016/S0167-8140(97)00220-X.
[13] Abolmaali N,Haase R,Koch A,et al.Two or four hour[18F]FMISO-PET in HNSCC.When is the contrast best?[J].Nuklearmedizin,2011,50(1):22-27.DOI:10.3413/nukmed-00328-10-07.
[14] Kikuchi M,Yamane T,Shinohara S,et al.18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma[J].Ann Nucl Med,2011,25(9):625-633.DOI:10.1007/s12149-011-0508-9.
[15] Yamane T,Kikuchi M,Shinohara S,et al.Reduction of[18F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma[J].Mol Imaging Biol,2011,13(2):227-231.DOI:10.1007/s11307-010-0365-2.
[16] Sato J,Kitagawa Y,Yamazaki Y,et al.18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma[J].J Nucl Med,2013,54(7):1060-1065.DOI:10.2967/jnumed.112.114355.
[17] Okamoto S,Shiga T,Uchiyama Y,et al.Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer[J].Ann Nucl Med,2014,28(2):81-87.DOI:10.1007/s12149-013-0781-x.
[18] Mortensen LS,Buus S,Nordsmark M,et al.Identifying hypoxia in human tumors:A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode[J].Acta Oncol,2010,49(7):934-940.DOI:10.3109/0284186X.2010.516274.
[19] Mortensen LS,Johansen J,Kallehauge J,et al.Faza PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy:results from the DAHANCA 24 trial[J].Radiother Oncol,2012,105(1):14-20.DOI:10.1016/j.radonc.2012.09.015.
[20] Minagawa Y,Shizukuishi K,Koike I,et al.Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer:a pilot study[J].Ann Nucl Med,2011,25(5):339-345.DOI:10.1007/s12149-011-0471-5.
[21] Vera P,Bohn P,Edet-Sanson A,et al.Simultaneous positron emission tomography(PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose(FDG),proliferation with 18F-fluoro-thymidine(FLT),and hypoxia with 18fluoro-misonidazole(F-miso) before and during radiotherapy in patients with non-small-cell lung cancer(NSCLC):a pilot study[J].Radiother Oncol,2011,98(1):109-116.DOI:10.1016/j.radonc.2010.10.011.
[22] Thureau S,Chaumet-Riffaud P,Modzelewski R,et al.Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3’-deoxy-3’-18F-fluorothymidine PET images in lung cancer[J].J Nucl Med,2013,54(9):1543-1550.DOI:10.2967/jnumed.112.118083.
[23] Bollineni VR,Kerner GS,Pruim J,et al.PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage Ⅲ-IV non-small cell lung cancer patients[J].J Nucl Med,2013,54(8):1175-1180.DOI:10.2967/jnumed.112.115014.
[24] Trinkaus ME,Blum R,Rischin D,et al.Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy[J].J Med Imaging Radiat Oncol,2013,57(4):475-481.DOI:10.1111/1754-9485.12086.
[25] Hu M,Xing L,Mu D,et al.Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer[J].Clin Nucl Med,2013,38(8):591-596.DOI:10.1097/RLU.0b013e318279fd3d.
[26] Li L,Hu M,Zhu H,et al.Comparison of 18F-Fluoroerythronitroimidazole and 18f-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer[J].Clin Lung Cancer,2010,11(5):335-340.DOI:10.3816/CLC.2010.n.042.
[27] Zegers CM,Van Elmpt W,Wierts R,et al.Hypoxia imaging with[18F]HX4 PET in NSCLC patients:defining optimal imaging parameters[J].Radiother Oncol,2013,109(1):58-64.DOI:10.1016/j.radonc.2013.08.031.
[28] Shibahara I,Kumabe T,Kanamori M,et al.Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole,a new 18F-labeled 2-nitroimidazole analog[J].J Neurosurg,2010,113(2):358-368.DOI:10.3171/2009.10.JNS09510.
[29] Beppu T,Terasaki K,Sasaki T,et al.Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral Oxygen pressure in glioblastoma[J].Mol Imaging Biol,2014,16(1):127-135.DOI:10.1007/s11307-013-0670-7.
[30] Schuetz M,Schmid MP,P?tter R,et al.Evaluating repetitive 18F-fluoroazomycin-arabinoside(18FAZA)PET in the setting of MRI guided adaptive radiotherapy in cervical cancer[J].Acta Oncol,2010,49(7):941-947.DOI:10.3109/0284186X.2010.510145.
[31] Vercellino L,Groheux D,Thoury A,et al.Hypoxia imaging of uterine cervix carcinoma with 18F-FETNIM PET/CT[J].Clin Nucl Med,2012,37(11):1065-1068.DOI:10.1097/RLU.0b013e3182638e7e.
[32] Cheng J,Lei L,Xu J,et al.18F-fluoromisonidazole PET/CT:a potential tool for predicting primary endocrine therapy resistance in breast cancer[J].J Nucl Med,2013,54(3):333-340.DOI:10.2967/jnumed.112.111963.
[33] Segard T,Robins PD,Yusoff IF,et al.Detection of hypoxia with 18F-fluoromisonidazole(18F-FMISO)PET/CT in suspected or proven pancreatic cancer[J].Clin Nucl Med,2013,38(1):1-6.DOI:10.1097/RLU.0b013e3182708777.
[34] Hugonnet F,Fournier L,Medioni J,et al.Metastatic renal cell carcinoma:relationship between initial metastasis hypoxia,change after 1 month’s sunitinib,and therapeutic response:an 18F-fluoromisonidazole PET/CT study[J].J Nucl Med,2011,52(7):1048-1055.DOI:10.2967/jnumed.110.084517.
[35] Havelund BM,Holdgaard PC,Rafaelsen SR,et al.Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer[J].Nucl Med Commun,2013,34(2):155-161.DOI:10.1097/MNM.0b013e32835bd5bc.
[36] Yue J,Yang Y,Cabrera AR,et al.Measuring tumor hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma:a pilot clinical study[J].Dis Esophagus,2012,25(1):54-61.DOI:10.1111/j.1442-2050.2011.01209.x.
[37] Staffurth J,Radiotherapy Development Board.A review of the clinical evidence for intensity-modulated radiotherapy[J].Clin Oncol(R Coll Radiol),2010,22(8):643-657.DOI:10.1016/j.clon.2010.06.013.
[38] Welsh L,Panek R,McQuaid D,et al.Prospective,longitudinal,multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer:the INSIGHT study[J].Radiat Oncol,2015,10:112.DOI:10.1186/s13014-015-0415-7.
[39] Fleckenstein J,Kremp K,Kremp S,et al.IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC:A direct comparison of PET-based treatment planning[J/OL].Strahlenther Onkol,2015[2015-09-09].http://link.springer.com/article/10.1007%2Fs00066-015-0900-9.[published online ahead of print Oct 5,2015].DOI:10.1007/s00066-015-0900-9.
[40] Maier FC,Kneilling M,Reischl G,et al.Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using[18F]-fluoro-azomycinarabino-furanoside([18F]FAZA)[J/OL].Radiat Oncol,2011,6:165[2015-09-09].http://www.ro-journal.com/content/6/1/165.DOI:10.1186/1748-717X-6-165.
[41] Cheng Y,Cheng H,Jiang C,et al.Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy[J/OL].Nat Commun,2015,6:8785[2015-09-09].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659941.DOI:10.1038/ncomms9785.
[42] Simpson JR,Bauer M,Perez CA,et al.Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer:Report of an rtog prospective randomized trial[J].Int J Radiat Oncol Biol Phys,1989,16(6):1483-1491.DOI:10.1016/0360-3016(89)90953-X.
[43] Hassan Metwally MA,Ali R,Kuddu M,et al.IAEA-HypoX.A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma[J].Radiother Oncol,2015,116(1):15-20.DOI:10.1016/j.radonc.2015.04.005.
[44] Zagorevskii D,Song M,Breneman C,et al.A mass spectrometry study of tirapazamine and its metabolites.insights into the mechanism of metabolic transformations and the characterization of reaction intermediates[J].J Am Soc Mass Spectrom,2003,14(8):881-892.DOI:10.1016/S1044-0305(03)00334-9.
[45] von Pawel J,von Roemeling R,Gatzemeier U,et al.Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer:A report of the international CATAPULT I study group.Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors[J].J Clin Oncol,2000,18(6):1351-1359.
[46] Rischin D,Peters L,Fisher R,et al.Tirapazamine,Cisplatin,and Radiation versus Fluorouracil,Cisplatin,and Radiation in patients with locally advanced head and neck cancer:a randomized phase Ⅱ trial of the Trans-Tasman Radiation Oncology Group(TROG 98.02)[J].J Clin Oncol,2005,23(1):79-87.DOI:10.1200/JCO.2005.01.072.
相似文献/References:
[1]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[2]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[3]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[4]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[5]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[6]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[11]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[12]陆东燕,侯莎莎,丁恩慈,等.结核性与恶性腹膜弥漫性病变的18F-FDG PET/CT影像特征分析[J].国际放射医学核医学杂志,2014,38(6):398.[doi:10.3760/cma.j.issn.1673-4114.2014.06.012]
Lu Dong-yan,Hou Sha-sha,Ding En-ci,et al.Analysis of 18F-FDG PET/CT imaging features of tuberculous and cancerous diffuse peritoneal lesions[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):398.[doi:10.3760/cma.j.issn.1673-4114.2014.06.012]
[13]刘春利,李毅红.18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值[J].国际放射医学核医学杂志,2013,37(2):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
LIU Chun-li,LI Yi-hong.The value of 18F-FDG PET/CT in diagnosing brain metastases from unknown primary tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
[14]王胜军,杨卫东,赵小虎,等.18F-FDG PET/CT诊断多发癌的价值[J].国际放射医学核医学杂志,2013,37(2):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
WANG Sheng-jun,YANG Wei-dong,ZHAO Xiao-hu,et al.Value of 18F-FDG PET/CT in the diagnosis of multiple primary malignant neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
[15]唐宇辉,陈跃.PET/CT在儿科恶性肿瘤中的应用进展[J].国际放射医学核医学杂志,2013,37(2):107.[doi:10.3760/cma.j.issn.1673-4114.2013.02.012]
TANG Yu-hui,CHEN Yue.The progression of PET/CT in pediatric malignant tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):107.[doi:10.3760/cma.j.issn.1673-4114.2013.02.012]
[16]孙爱君,任茜,刘健,等.11C-乙酸盐PET和PET/CT在肿瘤显像中的应用[J].国际放射医学核医学杂志,2013,37(4):243.[doi:10.3760/cma.j.issn.1673-4114.2013.04.013]
SUN Ai-jun,REN Qian,LIU Jian,et al.The application of 11C-acetate PET and PET-CT for tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):243.[doi:10.3760/cma.j.issn.1673-4114.2013.04.013]
[17]辛军,赵周社,李红,等.自适应统计迭代重建技术在PET/CT全身扫描中的应用[J].国际放射医学核医学杂志,2013,37(5):279.[doi:10.3760/cma.j.issn.1673-4114.2013.05.007]
XIN Jun,ZHAO Zhou-she,LI Hong,et al.Adaptive statistical iterative reconstruction technology in the application of PET/CT whole body scans[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):279.[doi:10.3760/cma.j.issn.1673-4114.2013.05.007]
[18]王玉婷,黄钢,蒋瑾,等.18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展[J].国际放射医学核医学杂志,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
WANG Yu-ting,HUANG Gang,JIANG Jin,et al.Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
[19]江茂情,吴华.18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用[J].国际放射医学核医学杂志,2012,36(6):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
JIANG Mao-qing,WU Hua.18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
[20]苏鸣岗,谭天秩.PET肿瘤筛查:一项存在争议的检查方法[J].国际放射医学核医学杂志,2012,36(6):358.[doi:10.3760/cma.j.issn.1673-4114.2012.06.009]
SU Ming-gang,TAN Tian-zhi.PET in cancer screening: a controversial imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):358.[doi:10.3760/cma.j.issn.1673-4114.2012.06.009]